Evista belongs to the drug family of selective estrogen receptor modulators. The drug has an agonist effect on non-reproductive tissues and as an antagonist – to reproduction. Its active component increases the concentration of binding globulin hormones (sex, thyroxine, corticosteroids) with a simultaneous increase in their total content in the blood without enhancement of the free fraction.
Many women after 50-55 years face a serious progressive disease, such as post-menopausal osteoporosis. Due to the imbalance of hormone production (in particular estradiol needed for the enrichment of bone calcium), the body does not receive the required minerals. This leads to bone thinning. Bone tissue becomes less dense, due to which even at low loads likely fractures.
The standard dosage for Evista is one tablet (60 mg of Raloxifene) per day for a long time treatment (determined individually). The intake of this dose can be administered any time of day, regardless of mealtime. Only adults )older than 18 years) can use Evista on a daily basis. Evista can’t be taken by pregnant or breast-feeding women of any age. The dosage can be adjusted in patients with liver or kidney problems. Consult a healthcare specialist on your dosage’s adjustment of Evista. The pill can be taken only inside, whole – without chewing or breaking.
For treatment or prevention of osteoporosis with Evista, vitamin D should be added to a person’s diet. The required daily dose of vitamin D during Evista treatment is 400-800 IU daily.
The long-time treatment is typically required. Women should use Evista pills along with calcium supplements. Evista can’t be used along with estrogen.
Contraindications to the use of Evista: hypersensitivity to any drug’s components; Thromboembolism; Pulmonary embolism; Retinal vein thrombosis; Deep vein thrombosis; Hepatic failure; Osteoporosis in men of reproductive age (in women).